Avidity Partners Management LP
DALLAS, TX · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$427.9M2026 Q3+ $60.3M options (notional, not included)
Positions18
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.97.8%
What Changed This Quarter?
Top Holdings
DNTH
Dianthus Therapeutics
34.3%
CGON
CG Oncology
19.6%
ORKA
Oruka Therapeutics
13.4%
CGONCALL
CG Oncology
12.3%
JBIO
Jade Biosciences
5.8%
ELVN
Enliven Therapeutics
5.2%
CATX
Perspective Therapeutics
3.4%
AKTS
Aktis Oncology
1.9%
New / Increased
1 new · 2 increased
CGONCALLNEW
CG Oncology
12.3%
JBIO
Jade Biosciences
5.8%
+17.6%
ORKA
Oruka Therapeutics
13.4%
+3.3%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.